Description
A third-generation SERM that selectively binds to human ERα (IC50 = 1.5 nM) and inhibits bone loss in ovariectomized rats; used in the treatment of postmenopausal osteoporosis and ER-positive breast cancer; also acts as an inverse agonist at the CB2 cannabinoid receptor
Formal name: (5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol, (2S,3S)-2,3-dihydroxybutanedioate
Synonyms: CP 336,156
Molecular weight: 563.6
CAS: 190791-29-8
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology||Research Area|Endocrinology & Metabolism|Bone Growth & Remodeling||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Estrogens & Progestins||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors